Pine River Capital Management’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Pine River Capital Management’s Portfolio IMNP Stock Details IMNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-12,500	Closed	-$4K	–	840
2015 Q4	$4K	Hold	12,500	–	–	﹤0.01%	658
2015 Q3	$108K	Hold	12,500	–	–	﹤0.01%	611
2015 Q2	$295K	Hold	12,500	–	–	﹤0.01%	632
2015 Q1	$260K	Hold	12,500	–	–	﹤0.01%	553
2014 Q4	$286K	Hold	12,500	–	–	﹤0.01%	620
2014 Q3	$653K	Buy	+12,500	New	+$890K	0.01%	710

Other funds holding IMNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EEG

E.E. Geduld $178M AUM 29.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

IFS

Ifrah Financial Services Little Rock, Arkansas $409M AUM 28.15% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pine River Capital Management's IMNP Position: Q1 2016 in Review

Pine River Capital Management sold out of Immune Pharmaceuticals Inc. (IMNP) in Q1 2016, closing a stake of 12,500 shares — an estimated $4K sold.

Pine River Capital Management first reported a position in IMNP in Q3 2014 and held it in 6 quarters. The position peaked at $653K in Q3 2014. 13 funds tracked by Wall St. Rank hold IMNP as of Q1 2016.

Pine River Capital Management reported no remaining Immune Pharmaceuticals Inc. position as of Q1 2016 after selling out during the quarter.
Pine River Capital Management sold 12,500 Immune Pharmaceuticals Inc. shares in Q1 2016, an estimated $4K.
Pine River Capital Management first reported a position in Immune Pharmaceuticals Inc. in Q3 2014 and held it in 6 quarters.
Pine River Capital Management's Immune Pharmaceuticals Inc. position peaked at $653K in Q3 2014.
13 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q1 2016.

Based on Pine River Capital Management's 13F filing for Q1 2016, filed 16 May 2016.